These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20642251)

  • 1. Tapentadol: an initial analysis.
    Prommer EE
    J Opioid Manag; 2010; 6(3):223-6. PubMed ID: 20642251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
    Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R
    Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
    Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tapentadol - how does it work in chronic pain?].
    MMW Fortschr Med; 2013 Sep; 155(16):44-5. PubMed ID: 24279155
    [No Abstract]   [Full Text] [Related]  

  • 13. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol immediate-release for acute pain.
    Hartrick CT
    Expert Rev Neurother; 2010 Jun; 10(6):861-9. PubMed ID: 20518601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol (Nucynta)--a new analgesic.
    Med Lett Drugs Ther; 2009 Aug; 51(1318):61-2. PubMed ID: 19661853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.
    Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM
    Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.